AAAAAA
Results:
1-13
|
Results: 13
Authors:
Chappuis, PO
Dieterich, B
Sciretta, V
Lohse, C
Bonnefoi, H
Remadi, S
Sappino, AP
Citation: Po. Chappuis et al., Functional evaluation of plasmin formation in primary breast cancer, J CL ONCOL, 19(10), 2001, pp. 2731-2738
Authors:
Bonnefoi, H
Biganzoli, L
Cufer, T
Mauriac, L
Hamilton, A
Schaefer, P
Piccart, M
Citation: H. Bonnefoi et al., An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of largeoperable or locally advanced/inflammatory breast cancer, BREAST CANC, 70(1), 2001, pp. 55-63
Authors:
Chen, XQ
Bonnefoi, H
Pelte, MF
Lyautey, J
Lederrey, C
Movarekhi, S
Schaeffer, P
Mulcahy, HE
Meyer, P
Stroun, M
Anker, P
Citation: Xq. Chen et al., Telomerase RNA as a detection marker in the serum of breast cancer patients, CLIN CANC R, 6(10), 2000, pp. 3823-3826
Authors:
Hugli, A
Sappino, AP
Anchisi, S
Mermillod, B
Schafer, P
Anguenot, JL
Bonnefoi, H
Citation: A. Hugli et al., Infusional ECarboF in patients with advanced breast cancer: A very active and well-tolerated out-patient regimen, ANN ONCOL, 11(12), 2000, pp. 1557-1561
Authors:
Hugli, A
Moro, D
Mermillod, B
Bolla, M
Alberto, P
Bonnefoi, H
Miralbell, R
Citation: A. Hugli et al., Phase II trial of up-front accelerated thoracic radiotherapy combined withchemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer, J CL ONCOL, 18(8), 2000, pp. 1662-1667
Authors:
Sabbioni, MEE
Siegrist, HP
Bacchi, M
Bernhard, J
Castiglione, M
Thurlimann, B
Bonnefoi, H
Perey, L
Herrmann, R
Goldhirsch, A
Hurny, C
Citation: Mee. Sabbioni et al., Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment, BREAST CANC, 59(3), 2000, pp. 279-287
Authors:
Chen, XQ
Bonnefoi, H
Diebold-Berger, S
Lyautey, J
Lederrey, C
Faltin-Traub, E
Stroun, M
Anker, P
Citation: Xq. Chen et al., Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer, CLIN CANC R, 5(9), 1999, pp. 2297-2303
Authors:
Bernhard, J
Castiglione-Gertsch, M
Schmitz, SFH
Thurlimann, B
Cavalli, F
Morant, R
Fey, MF
Bonnefoi, H
Goldhirsch, A
Hurny, C
Citation: J. Bernhard et al., Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonaltreatment, EUR J CANC, 35(6), 1999, pp. 913-920
Authors:
Sabbioni, MEE
Castiglione, M
Hurny, C
Siegrist, HP
Bacchi, M
Bernhard, J
Thurlimann, B
Bonnefoi, H
Perey, L
Goldhirsch, A
Senn, HJ
Citation: Mee. Sabbioni et al., Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, SUPP CARE C, 7(3), 1999, pp. 149-153
Authors:
Bonnefoi, H
Gore, ME
Citation: H. Bonnefoi et Me. Gore, Optimal cytoreduction in stage IV ovarian carcinoma - In reply, J CL ONCOL, 17(9), 1999, pp. 3004-3004
Authors:
Bernhard, J
Thurlimann, B
Schmitz, SFH
Castiglione-Gertsch, M
Cavalli, F
Morant, R
Fey, MF
Bonnefoi, H
Goldhirsch, A
Hurny, C
Citation: J. Bernhard et al., Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?, J CL ONCOL, 17(6), 1999, pp. 1672-1679
Authors:
Bonnefoi, H
A'Hern, RP
Fisher, C
Macfarlane, V
Barton, D
Blake, P
Shepherd, JH
Gore, ME
Citation: H. Bonnefoi et al., Natural history of stage IV epithelial ovarian cancer, J CL ONCOL, 17(3), 1999, pp. 767-775
Authors:
Chappuis, PO
Estreicher, A
Dieterich, B
Bonnefoi, H
Otter, M
Sappino, AP
Iggo, R
Citation: Po. Chappuis et al., Prognostic significance of p53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay, INT J CANC, 84(6), 1999, pp. 587-593
Risultati:
1-13
|